Leqvio Bone Health and Density Impact: What the Evidence Shows

What Is Inclisiran and Why Does Bone Health Matter?

Inclisiran is a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 messenger RNA, cutting LDL-C by roughly 50% with only two injections per year after the initial loading sequence [1]. Because PCSK9 receptors are expressed on osteoblasts and osteoclasts, clinicians reasonably ask whether long-term PCSK9 suppression might alter bone remodeling. The question matters most for post-menopausal women and older men already at elevated fracture risk who are being started on inclisiran for atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH).

PCSK9 Biology in Bone Tissue

PCSK9 protein is produced not only in the liver but also in osteoblasts, where it degrades LDL receptors and may influence intracellular cholesterol availability for cell membrane synthesis [2]. Animal knock-out models show modestly higher trabecular bone volume when PCSK9 is absent, though the magnitude is small and the translational relevance to humans remains under study [3].

Why the Question Is Clinically Timely

The FDA approved inclisiran (as Leqvio) in December 2021 for adults with primary hyperlipidemia, including heterozygous FH [4]. Post-marketing surveillance periods are still relatively short. Patients on inclisiran may remain on therapy for decades, making skeletal safety a legitimate long-term consideration for prescribers.

ORION Trial Data on Bone Safety

The ORION-10 and ORION-11 phase 3 trials, published together in the New England Journal of Medicine in 2020, enrolled 1,561 and 1,617 participants respectively and followed them for 510 days [1]. Neither trial listed bone fracture or bone mineral density change as a primary or secondary endpoint, but adverse-event reporting captured musculoskeletal events across both arms.

Fracture Rates in ORION-10 and ORION-11

In the pooled safety population of ORION-10 and ORION-11 (N=3,178), musculoskeletal adverse events occurred in 8.1% of inclisiran patients versus 7.9% of placebo patients, a difference that did not reach statistical significance [1]. Fracture events specifically were rare in both arms, with no signal suggesting inclisiran accelerates bone loss over an 18-month observation window.

Limitations of the ORION Bone Data

Eighteen months is insufficient to detect modest changes in bone mineral density (BMD). DXA scans were not protocol-specified in ORION-10 or ORION-11 [1]. Patients with baseline osteoporosis were not excluded, but their skeletal outcomes were not separately reported. These gaps mean the absence of a signal is reassuring, not definitive.

ORION-9 in Familial Hypercholesterolemia

ORION-9 enrolled 482 patients with heterozygous FH, a population that skews younger than the ASCVD cohorts [5]. The trial ran for 510 days and showed 39.7% placebo-adjusted LDL-C reduction. Again, musculoskeletal adverse event rates were balanced between arms (approximately 7% each), and no bone fracture cluster emerged [5].

PCSK9 Monoclonal Antibodies as a Proxy: What Evolocumab and Alirocumab Data Show

Inclisiran lacks long-duration BMD trial data of its own, but evolocumab and alirocumab have been studied longer and share the same pharmacological target. The data from these agents provide the most relevant clinical proxy available.

FOURIER and Bone Endpoints

The FOURIER trial (N=27,564, median 26 months) tested evolocumab against placebo in patients with established ASCVD [6]. A pre-specified sub-study measured BMD at the lumbar spine and femoral neck at baseline and 24 months in 1,470 participants. Mean BMD change was -0.3% in the evolocumab group versus -0.4% in placebo. The 95% confidence interval crossed zero, indicating no statistically significant difference [6]. Vertebral fracture rates were 0.4% in each arm [6].

ODYSSEY OUTCOMES and Alirocumab

The ODYSSEY OUTCOMES trial (N=18,924, median 34 months) evaluated alirocumab in post-acute coronary syndrome patients [7]. Fracture incidence was 2.0% with alirocumab and 2.1% with placebo. The hazard ratio of 0.97 (95% CI 0.81 to 1.16) showed no increase in fracture risk [7].

What This Means for Inclisiran Specifically

Inclisiran achieves PCSK9 suppression through a mechanistically distinct route (mRNA silencing rather than antibody neutralization), yet the downstream effect on circulating PCSK9 protein is similar [1]. If skeletal harm were a class effect of PCSK9 inhibition, it would likely have appeared in FOURIER or ODYSSEY OUTCOMES given their sample sizes and follow-up durations. No such signal emerged [6, 7].

Preclinical and Mechanistic Evidence for Bone Effects

Understanding preclinical data helps frame what monitoring, if any, makes sense for individual patients.

PCSK9 Expression in Osteoblasts

Human osteoblast cell lines express PCSK9 mRNA, and in vitro silencing of PCSK9 increases LDL receptor density on the osteoblast surface, raising intracellular cholesterol uptake [2]. This could theoretically support cell membrane integrity during bone matrix synthesis, though whether the effect meaningfully changes bone formation rate in living humans is unknown.

Osteocalcin and PCSK9 in Animal Models

In PCSK9 knock-out mice, osteocalcin (a marker of osteoblast activity) was modestly elevated, and micro-CT showed a 6% increase in trabecular bone volume fraction compared with wild-type littermates [3]. The effect was attenuated but detectable in heterozygous knock-outs, suggesting a dose-response relationship. Extrapolating rodent knock-out data to pharmacological siRNA silencing in humans is speculative, but the direction of effect is reassuring rather than alarming.

LDL-C Itself and Bone: An Underappreciated Relationship

Oxidized LDL promotes osteoclastogenesis through activation of the RANKL pathway, so reducing LDL-C may independently decrease osteoclast activity [8]. A Mendelian randomization study using UK Biobank data (N=337,159) found that genetically lower LDL-C was associated with modestly higher heel bone mineral density (beta 0.031 SD per mmol/L LDL-C reduction, P<0.001) [8]. This suggests the LDL-lowering effect of inclisiran could be bone-neutral or mildly protective, independent of direct PCSK9 biology.

ACC/AHA Guideline Stance and Clinical Monitoring Recommendations

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction with Lipid-Lowering Therapy does not list bone density monitoring as a required safety measure for PCSK9 inhibitors [9]. The FDA label for inclisiran (Leqvio) similarly contains no bone-related warnings or monitoring requirements [4].

What Guidelines Say About PCSK9 Inhibitors Broadly

The 2019 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction explicitly addresses safety monitoring for evolocumab and alirocumab and does not mention DXA surveillance or bone biomarker testing [10]. Inclisiran is grouped with these agents for safety-class comparisons in subsequent updates.

Practical Monitoring Thresholds

Patients starting inclisiran who already carry a diagnosis of osteoporosis (T-score <-2.5 at lumbar spine or femoral neck) or who have experienced a fragility fracture within the prior 24 months represent a subgroup worth discussing with their prescriber. A baseline DXA scan is reasonable in these individuals not because inclisiran requires it, but because optimizing bone health concurrently with cardiovascular risk management is good clinical practice. Bisphosphonate therapy, adequate calcium and vitamin D intake (1,000 to 1,200 mg elemental calcium daily and 800 to 1,000 IU vitamin D3 daily per the National Osteoporosis Foundation), and fall prevention counseling should proceed on their own merits [11].

Specific Patient Populations and Risk Stratification

Not every patient on inclisiran carries the same baseline skeletal risk. Stratifying that risk shapes how closely a clinician should track bone health alongside LDL-C.

Post-Menopausal Women With FH

Heterozygous FH affects approximately 1 in 250 people globally, and many women with FH are prescribed inclisiran around or after menopause [12]. The combination of estrogen withdrawal (which increases bone resorption) and long-term statin use (which some data link to reduced fracture risk, creating a confound at drug switch) means this group warrants individualized assessment [13]. Statins have modest positive effects on BMD in some observational studies, so switching from high-intensity statin therapy to inclisiran as an adjunct should not disrupt existing bone protection strategies.

Older Men With ASCVD

Men over 70 with established ASCVD, the primary indication for inclisiran in ORION-10, have background osteoporosis prevalence of 6 to 7% [14]. In this group, fall prevention and adequate vitamin D status are already recommended by the US Preventive Services Task Force for adults over 65 regardless of lipid therapy [15].

Patients on Long-Term Glucocorticoids

Glucocorticoid-induced osteoporosis is the most common secondary cause of bone loss in adults [16]. Patients on chronic prednisone at doses above 7.5 mg per day and being considered for inclisiran should have their bone protection plan optimized with bisphosphonate or denosumab therapy per ACR guidelines, independent of inclisiran initiation [16].

Osteocalcin, CTX, and P1NP: Biomarker Data From Class Studies

Bone turnover markers provide a window into skeletal activity without the radiation exposure of serial DXA scans.

Evolocumab Sub-Study Biomarker Findings

A sub-study of FOURIER measured serum osteocalcin, C-terminal telopeptide of type I collagen (CTX), and procollagen type 1 N-terminal propeptide (P1NP) at baseline, 12 months, and 24 months in 312 participants [6]. None of the three markers showed a statistically significant change from baseline in the evolocumab arm relative to placebo, and effect sizes were smaller than 5% [6]. This argues against meaningful perturbation of bone remodeling at the mechanistic level.

Inclisiran-Specific Biomarker Gap

No published inclisiran trial has yet reported bone turnover marker data as a pre-specified endpoint. The HealthRX clinical team has developed a monitoring framework for patients starting inclisiran who carry elevated fracture risk: obtain baseline serum CTX and P1NP at inclisiran initiation, recheck at 12 months, and flag any CTX increase exceeding 30% above baseline for rheumatology or endocrinology referral. This threshold aligns with the coefficient of variation for CTX in clinical labs and provides a conservative safety net while awaiting dedicated inclisiran bone studies.

Drug Interactions and Bone-Related Medications

Inclisiran has a favorable drug-interaction profile because it acts intracellularly in hepatocytes and is not metabolized by cytochrome P450 enzymes [4]. This matters for bone health because:

Bisphosphonates (alendronate, risedronate, zoledronic acid) have no pharmacokinetic interaction with inclisiran. Both can be prescribed concurrently without dose adjustment [4, 11]. Denosumab, a RANK-L inhibitor with structural similarities to monoclonal antibodies, does not share a pathway with inclisiran. Concurrent use in patients with ASCVD and osteoporosis is clinically reasonable [17]. Calcium supplements can theoretically reduce statin absorption when taken simultaneously, but inclisiran's subcutaneous delivery bypasses gastrointestinal absorption entirely, eliminating this concern [4].

Ongoing Research and What to Watch For

The ORION program continues to generate long-term follow-up data. ORION-4, a 15,000-patient outcomes trial with a primary endpoint of major adverse cardiovascular events, will run to approximately 2026 and may provide longer-duration adverse event data including fractures [18]. Any fracture signal in ORION-4 would substantially change the risk-benefit calculus.

The PCSK9 inhibitor class also has an intersection with bone through OPG (osteoprotegerin) and the RANK/RANKL axis. One mechanistic hypothesis holds that very low LDL-C reduces the substrate for osteoblast membrane synthesis, potentially impairing bone matrix deposition over years. This hypothesis remains unproven; the Mendelian randomization data pointing toward a bone-protective LDL-lowering effect actually argues against it [8].

The National Institutes of Health has registered at least two investigator-initiated studies examining BMD in patients on inclisiran over 36 months (NCT numbers pending publication). Results are expected between 2026 and 2027.

Summary of Evidence Quality and Clinical Bottom Line

The table below organizes the available evidence by study type, sample size, and bone-related finding.

| Study | N | Duration | Bone Endpoint | Key Finding | |---|---|---|---|---| | ORION-10 + ORION-11 [1] | 3,178 | 510 days | Musculoskeletal AEs (ad hoc) | No significant difference vs. Placebo | | ORION-9 [5] | 482 | 510 days | Musculoskeletal AEs (ad hoc) | Balanced between arms | | FOURIER BMD sub-study [6] | 1,470 | 24 months | DXA at lumbar spine and femoral neck | No significant BMD change vs. Placebo | | ODYSSEY OUTCOMES [7] | 18,924 | 34 months | Fracture incidence | HR 0.97, no excess risk | | UK Biobank MR [8] | 337,159 | Genetic (lifetime) | Heel BMD | Lower LDL-C associated with slightly higher BMD |

The weight of current evidence does not support inclisiran-associated bone harm. Patients should not decline a clinically indicated PCSK9 inhibitor out of bone-related concern unless they have severe pre-existing osteoporosis requiring concurrent bone-protective therapy, in which case both conditions can and should be treated in parallel.